Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer

Gaudet, Marc; Pharand-Charbonneau, Mathieu; Desrosiers, Marie-Pierre; Wright, Debbie; Haddad, Alain

doi:10.1016/j.brachy.2018.01.009

Cited by 9 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The one-week cohort consisted of 63 patients, who were treated with a median of 7 days between implants (range, 5-9). The two-week cohort consisted of 59 patients, who were treated with a median of 14 days between implants (range, [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. At baseline, the twoweek cohort had a higher mean PSA than the one-week cohort (8.02 vs. 6.46, p = 0.004) and had a higher rate of patients with PSA of 10-20 (34% vs. 13%, p = 0.04).…”

Section: Resultsmentioning

confidence: 99%

“…In a series similar to our dataset, Gaudet et al . reported on their single institutional results of treating thirty low- or intermediate-risk prostate cancer patients with 27 Gy over two implants, separated by 7-14 days [ 27 ]. They collected patient-reported health-related QOL results utilizing the IPSS and EPIC questionnaires and found 57% of patients treated experienced moderate to severe urinary symptoms at the one-month assessment after implantation, with a rapid recovery towards baseline over time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Harris¹,

Korpics²,

Sherwani³

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose: High-dose-rate (HDR) brachytherapy is an effective method of treating localized prostate cancer. There are limited data on the relationship between implant interval and outcomes. This study aims to assess if the implant interval between HDR treatments has an impact on patient-reported health-related quality of life (QOL) and physician-graded toxicity in men treated for localized prostate cancer. Material and methods: Patients were treated with HDR brachytherapy as monotherapy with 27 Gy in 2 fractions, given over two implants, performed 1-2 weeks apart. Patients were dichotomized into one-week and two-week cohorts. Patient-reported EPIC-26 genitourinary (GU), gastrointestinal (GI), and sexual QOL were assessed. Linear regression, chi-squared testing, and generalized linear mixed effect models were used to assess the differences in patient characteristics, patient-reported QOL, and physician-graded toxicity. Results: Outcomes of 122 patients were analyzed. Median follow-up was 18 months. Patient-reported GU and GI QOL worsened after treatment with a return towards baseline over time, while patient-reported sexual QOL worsened after treatment, but did not return towards baseline. There were no differences in patient-reported health related QOL as a function of implant interval. Maximum physician-graded GU, GI, and sexual toxicity rates of grade 2 or 3 were 68%, 3%, and 53%, respectively. There was no difference in rates of grade 2 or 3 toxicity as a function of implants interval. Conclusions: HDR brachytherapy for prostate cancer is a well-tolerated treatment. The interval between treatments is not associated with differences in patient-reported QOL or physician-graded toxicities.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Harris¹,

Korpics²,

Sherwani³

et al. 2020

jcb

View full text Add to dashboard Cite

show abstract

“…Modern imaging techniques have allowed for improved target delineation and treatment planning. In a series similar to ours, Gaudet et al reported on their single institutional results of treating 30 patients with low-or intermediate-risk prostate cancer with 27 Gy over two implants using CT-based treatment planning (25). They collected patient-reported hrQOL results using the IPSS and EPIC questionnaires and found 57% of patients treated experienced moderate to severe urinary symptoms at the 1-month assessment after implantation, with a rapid recovery toward baseline over time.…”

Section: Discussionmentioning

confidence: 68%

Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life

Harris

Deirmenjian

et al. 2021

Brachytherapy

View full text Add to dashboard Cite

High-dose-rate (HDR) prostate brachytherapy uses volumetric imaging for treatment planning. Our institution transitioned from computed tomography (CT)-based planning to MRIbased planning with the hypothesis that improved visualization could reduce treatment-related toxicity. This study aimed to compare the patient-reported health-related quality of life (hrQOL) and physician-graded toxicity outcomes of CT-based and MRI-based HDR prostate brachytherapy. METHODS: From 2016 to 2019, 122 patients with low-or intermediate-risk prostate cancer were treated with HDR brachytherapy as monotherapy. Patients underwent CT only or CT and MRI imaging for treatment planning and were grouped per treatment planning imaging modality. Patientreported hrQOL in the genitourinary (GU), gastrointestinal (GI), and sexual domains was assessed using International Prostate Symptom Score and Expanded Prostate Cancer Index Composite Short Form-26 questionnaires. Baseline characteristics, changes in hrQOL scores, and physician-graded toxicities were compared between groups. RESULTS: The median follow-up was 18 months. Patient-reported GU, GI, and sexual scores worsened after treatment but returned toward baseline over time. The CT cohort had a lower baseline mean International Prostate Symptom Score (5.8 vs. 7.8, p 5 0.03). The other patient-reported GU and GI scores did not differ between groups. Overall, sexual scores were similar between the CT and MRI cohorts ( p 5 0.08) but favored the MRI cohort at later follow-up with a smaller decrease in Expanded Prostate Cancer Index Composite Short Form-26 sexual score from baseline at 18 months (4.9 vs. 19.8, p 5 0.05). Maximum physician-graded GU, GI, and sexual toxicity rates of grade $2 were 68%, 3%, and 53%, respectively, with no difference between the cohorts ( p 5 0.31). CONCLUSION: Our study shows that CT-and MRI-based HDR brachytherapy results in similar rates of GU and GI toxicity. MRI-based planning may result in improved erectile function recovery compared with CT-based planning. Published by Elsevier Inc. on behalf of American Brachytherapy Society.

show abstract

“… 3 , 22 , 23 HDR monotherapy has been shown to have acceptable rates of toxicity that are comparable to other modalities, with a general trend of modestly increased acute urinary symptoms and fewer bowel symptoms. 24 , 25 …”

Section: Discussionmentioning

confidence: 99%

Normal Tissue Integral Dose as a Result of Prostate Radiation Therapy: A Quantitative Comparison Between High-Dose-Rate Brachytherapy and Modern External Beam Radiation Therapy Techniques

Grzywacz

Arden

Mankuzhy³

et al. 2023

Advances in Radiation Oncology

View full text Add to dashboard Cite

Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer

Cited by 9 publications

References 25 publications

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life

Normal Tissue Integral Dose as a Result of Prostate Radiation Therapy: A Quantitative Comparison Between High-Dose-Rate Brachytherapy and Modern External Beam Radiation Therapy Techniques

Contact Info

Product

Resources

About